AbbVie (ABBV) EPS Beats Consensus, Updates Guidance
AbbVie (NYSE: ABBV) reported Q1 EPS of $2.46, better than the analyst estimate of $2.39. Revenue for the quarter came in at $13.34 billion versus the consensus estimate of $12.93 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $12.09-$12.29, versus the consensus of $12.18.
- AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.99 - $12.19 to $12.09 - $12.29, which includes an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2025. The company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2025, as both cannot be reliably forecasted. This guidance does not reflect the acquired IPR&D and milestones impact related to AbbVie and Gubra's licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025. Additionally, this guidance is based on the existing trade environment and does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie's business.
(Updated with correct EPS consensus)
For earnings history and earnings-related data on AbbVie (ABBV) click here.